**Purpose:** All genetically female at birth individuals are at risk for developing breast cancer. No guidelines exist for the surveillance of breast cancer in these patients particularly for those choosing to undergo female-to-male transgender top surgery. We aim to investigate current experiences and perioperative practices among American Society of Plastic Surgery (ASPS) member surgeons performing top surgery.

**Method:** An anonymous, 19 question electronic survey was sent to ASPS surgeons. General proportions were calculated from the survey responses.

**Results:** Of the 107 respondents, only 71 (67%) perform top surgery. 28% routinely remove all breast tissue that they encounter and 74% send all specimens for pathologic analysis. High cost to patients was the greatest barrier to sending specimens to pathology. 8.7% reported having had a diagnosis of breast cancer or pre-cancerous finding within a specimen, and 4.4% have had a patient or cared for a patient diagnosed with breast cancer after top surgery. DCIS and atypical ductal hyperplasia were the most commonly found pathologic diagnoses. 85% require breast imaging prior to top surgery in patients over 40 years old. Only 70% counsel patients on postoperative breast cancer screening. Most commonly recommended screening regimens were self and medical professional breast exams.

**Conclusions:** Wide variation exists in the management of pre-, intra-, and postoperative breast cancer screening for patients undergoing female-to-male transgender top surgery. Our data highlights the need for standardization of care and further studies documenting the risk, incidence, and prevalence of breast cancer in the transmasculine population before and after chest surgery.
